Update analysis of NEJ009: Gefitinib alone (G) versus gefitinib plus chemotherapy (GCP) for non-small cell lung cancer with mutated EGFR.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.9081
Abstract: 9081 Background: NEJ009 study is the first randomized phase III trial that compared gefitinib plus chemotherapy with gefitinib in patients with untreated NSCLC harboring EGFR mutations. We report an updated OS and long-term tolerability analysis,… read more here.
Keywords: pfs pfs2; gefitinib plus; gcp; plus chemotherapy ... See more keywords
Efficacy and Safety of Gefitinib Plus Pemetrexed/Platinum in Advanced EGFR-Mutated Lung Adenocarcinoma Patients: A Real-World Observational Study
Sign Up to like & getrecommendations! Published in 2022 at "OncoTargets and therapy"
DOI: 10.2147/ott.s332998
Abstract: Background Recent clinical trials illustrated that gefitinib plus pemetrexed/platinum regimen improves survival in advanced lung adenocarcinoma patients with EGFR mutation, while data on its efficacy and safety in a real clinical setting are limited. Thus,… read more here.
Keywords: lung adenocarcinoma; pfs; pemetrexed platinum; group ... See more keywords
Cost-Effectiveness Analysis of Gefitinib Alone and Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Small-Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Risk Management and Healthcare Policy"
DOI: 10.2147/rmhp.s352827
Abstract: Background The rational choice of drugs for treating patients with advanced non-small-cell lung cancer (NSCLC) is significantly impacted by changes in modern drug policy, health insurance negotiation, and budget impact analyses. Here, we provide a… read more here.
Keywords: plus chemotherapy; cost; gefitinib; patients advanced ... See more keywords